Risk Factors for Appendiceal Metastasis with Epithelial Ovarian Cancer

Kokanali, Mahmut Kuntay; Güzel, Ali İrfan; Erkılınç, Selçuk; Tokmak, Aytekin; Topçu, Hasan Onur; Güngör, Tayfun

doi:10.7314/apjcp.2014.15.6.2689

Cited by 4 publications

(2 citation statements)

References 13 publications

(19 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this study we had only four cases with history of appendectomy. One study which was carried out in Turkey in 2014 27 , found that the epithelial ovarian cancer, stage, grade, presence of ascitis, right-sided location and large tumor size had importance for estimation the risk of appendicular 28 showed that prior appendectomy was not protective against development of malignant or borderline ovarian cancer. In our study more than half of cases were menstruated at age of 11 years and above.…”

Section: Discussionmentioning

confidence: 99%

Risk factors among patients with ovarian cancer attending oncology hematology center in Basrah city

Ahmed¹

2022

BJSRG

View full text Add to dashboard Cite

Worldwide, approximately 225,500 ovarian cancers are diagnosed annually. The leading cause of gynecological cancer death (140,200 worldwide annually) is the ovarian cancer, which accounts for more deaths than all the other gynecological cancers combined. The ovarian cancer is the fourteenth commonest cancer among population in Basrah city in Iraq.This is a case control study carried out in the Basrah oncology -hematology center and primary health care centers in Basrah city. The study include 103 cases of ovarian cancer and 206 control. We found that more than half of case of ovarian cancer aged 50 years and above. History of insulin treatment is a risk factor for ovarian cancer (OR more than one) with significant statistical association. Hysterectomy and tubal ligation are protective against ovarian cancer .There are many risk factors of ovarian cancer some of these are modifiable while the others are not modifiable. Hysterectomy and tubal ligation considered as protective factors.

show abstract

Section: Discussionmentioning

confidence: 99%

Risk factors among patients with ovarian cancer attending oncology hematology center in Basrah city

Ahmed¹

2022

BJSRG

View full text Add to dashboard Cite

show abstract

“…With surgery and standard IV CT, most patients achieve complete clinical remission (Gaemmaghami et al, 2011). However, disease recurrence occurs in approximately 80% of patients and usually involves the peritoneal cavity (Sarkar et al, 2013;Suprasert and Chalapati, 2013;Liu et al, 2014;Kokanali et al, 2014).…”

Section: Introductionmentioning

confidence: 99%

Intra-Peritoneal Cisplatin Combined with Intravenous Paclitaxel in Optimally Debulked Stage 3 Ovarian Cancer Patients: An Izmir Oncology Group Study

Ünal

Yılmaz²,

Yavuzşen³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: The advantage of intra-peritoneal (IP) chemotherapy (CT) in the initial management of ovarian cancer after cytoreductive surgery is well known. The feasibility and toxicity of a treatment regimen with an IP + intravenous CT (IPIVCT) for optimally debulked stage III ovarian cancer were here evaluated retrospectively. Materials and Methods: A total of 30 patients were treated in our institution between October 2006 and February 2011. Patients received IV paclitaxel 175 mg/m 2 over 3 hours followed by IP cisplatin 75 mg/m 2 on day 1; they also received IP paclitaxel 60 mg/m 2 on day 8. They were also scheduled to receive 6 courses of CT every 21 days. Results: The median age of the patients was 55 years (35-77), and the majority had papillary serous ovarian cancer (63.3%). The patients completed a total of 146 cycles of IPIVCT. Twenty-eight were able to receive at least three cycles of IPIVCT and 18 (60%) completed the scheduled 6 cycles. Two patients discontinued the IPIVCT because of toxicity of chemotherapy agents and 6 had to stop treatment due to intolerable abdominal pain during IP drug administration, obstruction and impaired access. Grade 3/4 toxicities included neutropenia (6 patients; 20%), anemia (2 patients; 6.7%) and nausea-vomiting (2 patients; 6.7%). Doses were delayed in 12 cycles (8%) for neutropenia (n=6), thrombocytopenia (n=3) and elevated creatinine (n=3). Drug doses were not reduced. The median duration of progression-free survival (PFS) was 47.7 months (95%CI, 38.98-56.44) and overall survival (OS) was 51.7 months (95%CI, 44.13-59.29). Two and five-year overall survival rates were 75.6 % and 64.8%, respectively. Conclusions: IPIVCT is feasible and well-tolerated in this setting. Its clinically proven advantages should be taken into consideration and more efforts should be made to administer IPIVCT to suitable patients.

show abstract

Aptamer-based carbohydrate antigen 125 sensor with molybdenum disulfide functional hybrid materials

Qin

Gao

et al. 2023

Analytical Biochemistry

View full text Add to dashboard Cite

Risk Factors for Appendiceal Metastasis with Epithelial Ovarian Cancer

Cited by 4 publications

References 13 publications

Risk factors among patients with ovarian cancer attending oncology hematology center in Basrah city

Risk factors among patients with ovarian cancer attending oncology hematology center in Basrah city

Intra-Peritoneal Cisplatin Combined with Intravenous Paclitaxel in Optimally Debulked Stage 3 Ovarian Cancer Patients: An Izmir Oncology Group Study

Aptamer-based carbohydrate antigen 125 sensor with molybdenum disulfide functional hybrid materials

Contact Info

Product

Resources

About